Results 31 to 40 of about 9,243 (198)

Febuxostat-induced acute liver injury [PDF]

, 2016
Febuxostat is a unique xanthine oxidase inhibitor that was approved for the prevention of gout in the United States in 2009. Unlike allopurinol, febuxostat is not a nucleoside analogue and has a higher specificity for xanthine oxidase. Although this drug
Bohm, Matt, Chalasani, Naga, Vuppalanchi, Raj   +2 more
core   +1 more source

Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis

Arthritis Research & Therapy, 2018
Background The purpose of this study was to assess the comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults.
Jasvinder A. Singh, John D. Cleveland
doaj   +1 more source

Screening of DUB activity and specificity by MALDI-TOF mass spectrometry [PDF]

, 2014
Deubiquitylases (DUBs) are key regulators of the ubiquitin system which cleave ubiquitin moieties from proteins and polyubiquitin chains. Several DUBs have been implicated in various diseases and are attractive drug targets. We have developed a sensitive
A Iphofer, A Kovalenko, A van der Horst, AC Faesen, AK Al-Hakim, AM Oliveira, B Nicholson, C Kondapalli, C Reverdy, D Bungert, D Komander, D Komander, D Komander, DW Lee, E Graner, E Szajli, EW Harhaj, F Colland, F El Oualid, F Ikeda, FE Reyes-Turcu, G Nicastro, H Mistry, HB Kramer, J Chen, J Hemelaar, J Liang, J McCullough, JF McGouran, JW Pierce, K Keusekotten, K Saigoh, L Daviet, LC Dang, LV Pham, M Altun, M Colombo, M Karas, M Li, M Pulvino, MJ Clague, MJ Lee, MK Hospenthal, N Krishnan, NL Anderson, OW Huang, P Cohen, P Rufenacht, R Ekkebus, RA Horton, S Strickson, S Virdee, SD Sherrod, SJ Orcutt, SM Nijman, SM Nijman, SP Shah, TE Messick, TE Mevissen, U Hassiepen, Y Liu, Y Takano, Y Zhang   +62 more
core   +3 more sources

Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study

Therapeutic Advances in Musculoskeletal Disease, 2022
Background: To evaluate the safety, tolerability, and efficacy of SHR4640, a highly selective urate transporter-1 inhibitor, in combination with febuxostat, in patients with primary hyperuricemia.
Honghu Tang, Beibei Cui, Yiyu Chen, Lin Chen, Zhihong Wang, Ning Zhang, Yanlan Yang, Xiaodong Wang, Xiangliang Xie, Lingyun Sun, Wantai Dang, Xianyang Wang, Runzi Li, Jianjun Zou, Yi Zhao, Yi Liu   +15 more
doaj   +1 more source

Xanthine oxidoreductase regulates macrophage IL1β secretion upon NLRP3 inflammasome activation. [PDF]

, 2015
Activation of the NLRP3 inflammasome by microbial ligands or tissue damage requires intracellular generation of reactive oxygen species (ROS). We present evidence that macrophage secretion of IL1β upon stimulation with ATP, crystals or LPS is mediated by
Busso, N., Ives, A., LeRoy, D., Martinon, F., Miner, J.N., Nomura, J., Roger, T., Simon, G., So, A.   +8 more
core   +1 more source

A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout

Rheumatology and Therapy, 2019
Introduction This 24-week randomized, double-blind, non-inferiority study compared the efficacy and safety of febuxostat, a xanthine oxidase inhibitor, with allopurinol using an up-titration method in hyperuricemic Chinese subjects with or without gout ...
Fengchun Zhang, Zhichun Liu, Lindi Jiang, Hao Zhang, Dongbao Zhao, Yang Li, Hejian Zou, Xiaoyue Wang, Xiangpei Li, Bingyin Shi, Jianhua Xu, Hongjie Yang, Shaoxian Hu, Shen Qu   +13 more
doaj   +1 more source

A novel drug management system in the Febuxostat versus Allopurinol Streamlined Trial:A description of a pharmacy system designed to supply medications directly to patients within a prospective multicenter randomised clinical trial [PDF]

, 2016
Background: Trials of investigational medicinal products are required to adhere to strict guidelines with regard to the handling and supply of medication.
Flynn, Robert W V, Macdonald, Thomas M., Mackenzie, Isla S., McDonnell, Patrick, Rogers, Amy   +4 more
core   +2 more sources

Efficacy and Safety of Different Doses of Urico-Lowering Agents in The Treatment of Gout with Hyperuricemia: A Systematic Review and Network Meta-Analysis [PDF]

BIO Web of Conferences
Objectives: To systematically evaluate the efficacy and safety of different doses of uric acid- lowering drugs (allopurinol, febuxostat, and benzbromarone) in patients with gout with hyperuricemia by using the method of reticulated Meta-analysis. Methods:
Wen Jie, Wang Yongyan, Li Jialin, Zhang Yiying, Shi Yan, Li Xingzhou, Sun Xuewei   +6 more
doaj   +1 more source

Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.

PLoS Medicine, 2020
BackgroundAn elevated level of serum uric acid (SUA) is associated with an increased risk of cardiovascular disease. Pharmacological intervention with urate-lowering agents, such as the conventional purine analogue xanthine oxidase (XO) inhibitor ...
Atsushi Tanaka, Isao Taguchi, Hiroki Teragawa, Nobukazu Ishizaka, Yumiko Kanzaki, Hirofumi Tomiyama, Masataka Sata, Akira Sezai, Kazuo Eguchi, Toru Kato, Shigeru Toyoda, Ryoichi Ishibashi, Kazuomi Kario, Tomoko Ishizu, Shinichiro Ueda, Koji Maemura, Yukihito Higashi, Hirotsugu Yamada, Mitsuru Ohishi, Kotaro Yokote, Toyoaki Murohara, Jun-Ichi Oyama, Koichi Node, PRIZE study investigators   +23 more
doaj   +1 more source

Acute kidney injury in critically ill cancer patients : an update [PDF]

, 2016
Patients with cancer represent a growing group among actual ICU admissions (up to 20 %). Due to their increased susceptibility to infectious and noninfectious complications related to the underlying cancer itself or its treatment, these patients ...
Benoit, Dominique, Lameire, Norbert, Van Biesen, Wim, Vanholder, Raymond   +3 more
core   +2 more sources